Bcl-2 and bax protein expression in indolent versus aggressive B-cell non-hodgkin's lymphomas

作者: Susan Wheaton , Julie Netser , Donald Guinee , Mark Rahn , Sherrie Perkins

DOI: 10.1016/S0046-8177(98)90451-8

关键词:

摘要: Bcl-2 and bax are cellular proteins that important in the regulation of apoptosis. Overexpression bcl-2 protein is associated with prolonged cell survival, whereas overexpression correlates increased apoptosis after injury. It has been suggested ratio determines a cell's susceptibility to We studied expression by immunohistochemical methods 46 cases B-cel non-Hodgkin's lymphoma characterized Revised European-American Lymphoma (REAL) classification determine whether these two correlated histological subtype or predicted clinical behavior (indolent v aggressive). For each case, both percentage cells staining as well intensity were recorded, bcl-2-bax (BBPR) was calculated. Bax identified 100% lymphomas studied. In contrast, seen only 67%. positive small lymphocytic lymphomas, 80% follicle center 38% diffuse large 33% high-grade B-cell Burkitt's-like 0% Burkitt's lymphoblastic lymphomas. The BBPR indolent (mean, 1.8) significantly greater than aggressive 0.6) (P < = .002). This suggests may be linked biological

参考文章(30)
Morton Coleman, Morton Coleman, Leonard Saltz, Leonard Saltz, Peter I. Yi, Arthur A. Topilow, Arthur A. Topilow, Bernard Bernhardt, Bernard Bernhardt, Kenneth Adler, Kenneth Adler, Larry Norton, Larry Norton, Chemotherapy for large cell lymphoma: A status update Seminars in Oncology. ,vol. 17, pp. 60- 73 ,(1990) , 10.5555/URI:PII:0093775490901502
V. Ferrans, E. Brambilla, D. Guinee, T. Hayashi, M. Koss, W. Travis, M. Rahn, M. Fleming, The potential role of BAX and BCL-2 expression in diffuse alveolar damage. American Journal of Pathology. ,vol. 151, pp. 999- 1007 ,(1997)
Thomas A, El Rouby S, Krajewski S, Reed Jc, Newcomb Ew, Potmesil M, Silber R, Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene. ,vol. 12, pp. 1055- 1062 ,(1996)
Randy D. Gascoyne, Sheryle A. Adomat, Stanislaw Krajewski, Maryla Krajewska, Douglas E. Horsman, Anthony W. Tolcher, Susan E. O'Reilly, Paul Hoskins, Andrew J. Coldman, John C. Reed, Joseph M. Connors, Prognostic Significance of Bcl-2 Protein Expression and Bcl-2 Gene Rearrangement in Diffuse Aggressive Non-Hodgkin's Lymphoma Blood. ,vol. 90, pp. 244- 251 ,(1997) , 10.1182/BLOOD.V90.1.244
L Campos, JP Rouault, O Sabido, P Oriol, N Roubi, C Vasselon, E Archimbaud, JP Magaud, D Guyotat, High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy Blood. ,vol. 81, pp. 3091- 3096 ,(1993) , 10.1182/BLOOD.V81.11.3091.3091
David J McConkey, Joya Chandra, Michael Keating, Timothy J McDonnell, William K Plunkett, Susan Wright, John C. Reed, Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. Journal of Immunology. ,vol. 156, pp. 2624- 2630 ,(1996)